Roger H. Brookes

Roger H. Brookes

Auto-generated profile, based on publicly available information

Roger H. Brookes

Sanofi Pasteur, Toronto, ON, Canada

Research Focus & Metrics

Academic Career Length

43Years (1984-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 September 1997 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
ALAjit Lalvani
Ajit Lalvani
RBRoger Brookes
Roger Brookes
SHSophie Hambleton
Sophie Hambleton
WBWarwick J. Britton
Warwick J. Britton
AHAdrian V.S. Hill
Adrian V.S. Hill
AMAndrew J. McMichael
Andrew J. McMichael
The nature of the CD8+ T cells that underlie antiviral protective immunological memory in vivo is unclear. We have characterized peptide-specific CD8+ T lymphocytes directly ex vivo from peripheral blood in humans with past exposure to influenza virus, using single cell interferon γ (IFN-γ) release as a measure of effector function. In individuals in the memory state with respect to influenza virus infection, unrestimulated antigen-specific CD8+ T cells displayed IFN-γ release within 6 h of antigen contact, identifying a population of memory CD8+ T cells that exhibit effector function without needing to divide and differentiate over several days. We have quantified circulating CD8+ effector T cells specific for six different MHC class I–restricted influenza virus epitopes. Enumeration of these CD8+ T cells gives frequencies of peptide-specific T cells that correlate with, but are in general severalfold higher than, CTL precursor frequencies derived from limiting dilution analysis, indicating that this novel population of memory CD8+ T cells has hitherto been undetected by standard means. The phenotype of these cells, which persist at a low frequency long after recovery from an acute viral infection, suggests that they play a role in protective immunological memory.

1 August 2003 in The Journal of Immunology
Verified
Journal Article
Closed access
PDF file
NGNilu P. Goonetilleke
Nilu P. Goonetilleke
HMHelen McShane
Helen McShane
CHCarolyn M. Hannan
Carolyn M. Hannan
RARichard J. Anderson
Richard J. Anderson
RBRoger H. Brookes
Roger H. Brookes
AHAdrian V. S. Hill
Adrian V. S. Hill
Heterologous prime-boost immunization strategies can evoke powerful T cell immune responses and may be of value in developing an improved tuberculosis vaccine. We show that recombinant modified vaccinia virus Ankara, expressing Mycobacterium tuberculosis Ag 85A (M.85A), strongly boosts bacille Calmette-Guérin (BCG)-induced Ag 85A specific CD4+ and CD8+ T cell responses in mice. A comparison of intranasal (i.n.) and parenteral immunization of BCG showed that while both routes elicited comparable T cell responses in the spleen, only i.n. delivery elicited specific T cell responses in the lung lymph nodes, and these responses were further boosted by i.n. delivery of M.85A. Following aerosol challenge with M. tuberculosis, i.n. boosting of BCG with either BCG or M.85A afforded unprecedented levels of protection in both the lungs (2.5 log) and spleens (1.5 log) compared with naive controls. Protection in the lung correlated with the induction of Ag 85A-specific, IFN-γ-secreting T cells in lung lymph nodes. These findings support further evaluation of mucosally targeted prime-boost vaccination approaches for tuberculosis.

6 January 1998 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
ALAjit Lalvani
Ajit Lalvani
RBRoger Brookes
Roger Brookes
RWRobert J. Wilkinson
Robert J. Wilkinson
AMAdam S. Malin
Adam S. Malin
APAnsar A. Pathan
Ansar A. Pathan
AHAdrian V. S. Hill
Adrian V. S. Hill
Protective immunity toMycobacterium tuberculosisis poorly understood, but mounting evidence, at least in animal models, implicates major histocompatibility complex class I-restricted CD8+T cells as an essential component. By using a highly sensitive assay for single cell interferon γ release, we screened an array ofM. tuberculosisantigen-derived peptides congruent with HLA class I allele-specific motifs. We identified CD8+T cells specific for epitopes in the early secretory antigenic target 6 during active tuberculosis, after clinical recovery and in healthy contacts. Unrestimulated cells exhibited peptide-specific interferon γ secretion, whereas lines or clones recognized endogenously processed antigen and showed cytolytic activity. These results provide direct evidence for the involvement of CD8+cytotoxic T lymphocytes in host defense againstM. tuberculosisin humans and support current attempts to generate protective cytotoxic T lymphocyte responses againstM. tuberculosisby vaccination.

1 July 1996 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
TLThomas Lehner
Thomas Lehner
YWYufei Wang
Yufei Wang
MCMartin Cranage
Martin Cranage
LBLesley A. Bergmeier
Lesley A. Bergmeier
EMElaine Mitchell
Elaine Mitchell
RWRobert Ward
Robert Ward

1 February 2001 in Infection and Immunity
Verified
Journal Article
Open access
PDF file
HMHelen McShane
Helen McShane
RBRoger Brookes
Roger Brookes
SGSarah Gilbert
Sarah Gilbert
AHAdrian V. S. Hill
Adrian V. S. Hill
DNA vaccines whose DNA encodes a variety of antigens fromMycobacterium tuberculosishave been evaluated for immunogenicity and protective efficacy. CD8+T-cell responses and protection achieved in other infectious disease models have been optimized by using a DNA immunization to prime the immune system and a recombinant virus encoding the same antigen(s) to boost the response. A DNA vaccine (D) and recombinant modified vaccinia virus Ankara (M) in which the DNA encodes early secreted antigenic target 6 and mycobacterial protein tuberculosis 63 synthesized, and each was found to generate specific gamma interferon (IFN-γ)-secreting CD4+T cells. Enhanced CD4+IFN-γ T-cell responses were produced by both D-M and M-D immunization regimens. Significantly higher levels of IFN-γ were seen with a D-D-D-M immunization regimen. The most immunogenic regimens were assessed in a challenge study and found to produce protection equivalent to that produced byMycobacterium bovisBCG. Thus, heterologous prime-boost regimens boost CD4+as well as CD8+T-cell responses, and the use of heterologous constructs encoding the same antigen(s) may improve the immunogenicity and protective efficacy of DNA vaccines against tuberculosis and other diseases.

1 February 2006 in Clinical and Vaccine Immunology
Verified
Journal Article
Closed access
PDF file
ADAbebech Demissie
Abebech Demissie
ELEliane M. S. Leyten
Eliane M. S. Leyten
MAMarkos Abebe
Markos Abebe
LWLiya Wassie
Liya Wassie
AAAbraham Aseffa
Abraham Aseffa
TGthe VACSEL Study Group
the VACSEL Study Group
Mycobacterium tuberculosis is estimated to infect 80 to 100 million people annually, the majority of whom do not develop clinical tuberculosis (TB) but instead maintain the infection in a latent state. These individuals generally become positive in response to a tuberculin skin test and may develop clinical TB at a later date, particularly if their immune systems are compromised. Latently infected individuals are interesting for two reasons. First, they are an important reservoir of M. tuberculosis , which needs to be considered for TB control. Second, if detected prior to recrudescence of the disease, they represent a human population that is making a protective immune response to M. tuberculosis , which is very important for defining correlates of protective immunity. In this study, we show that while responsiveness to early secretory antigenic target 6 is a good marker for M. tuberculosis infection, a strong response to the 16-kDa Rv2031c antigen (HspX or α-crystallin) is largely restricted to latently infected individuals, offering the possibility of differential immunodiagnosis of, or therapeutic vaccination against, TB.